You just read:

Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint

News provided by

Eli Lilly and Company

Apr 04, 2018, 06:45 ET